RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
CUNEO A
Collezione AO Cuneo
Items : 57
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study. in Hematological oncology / Hematol Oncol. 2023 Sep 29. doi: 10.1002/hon.3216.
2023
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Reda G; Caira M; Gozzetti A; Coscia M; Zamprogna G; Albano F; Cuneo A; Pane F; Vallisa D; Trentin L; Mauro FR; Albi E; Gaidano G; Chiarenza A; Laurenti L; Sportoletti P; Finsinger P; Gualberti G; Iannella E; Malgieri S; Molica S;
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study. in American journal of hematology / Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29.
2023
AO Cuneo
AOU Città della Salute di Torino
Visentin A; Mauro FR; Scarfò L; Gentile M; Farina L; Reda G; Ferrarini I; Proietti G; Derenzini E; Cibien F; Vitale C; Sanna A; Pietrasanta D; Marchetti M; Murru R; Rigolin GM; Sportoletti P; Trimarco V; Cavarretta CA; Angotzi F; Cellini A; Ruocco V; Zatta I; Laurenti L; Molica S; Coscia M; Ghia P; Foà R; Cuneo A; et alii...
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib. in Blood cancer journal / Blood Cancer J. 2023 May 3;13(1):65. doi: 10.1038/s41408-023-00834-6.
2023
AO Cuneo
Palandri F; Elli EM; Auteri G; Bonifacio M; Benevolo G; Heidel FH; Paglia S; Trawinska MM; Bosi C; Rossi E; Tiribelli M; Tieghi A; Iurlo A; Polverelli N; Caocci G; Binotto G; Cavazzini F; Beggiato E; Cilloni D; Tatarelli C; Mendicino F; Miglino M; Bocchia M; Crugnola M; Mazzoni C; Romagnoli AD; Rindone G; Ceglie S; D'Addio A; et alii...
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. in Cancer / Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18.
2023
AOU Città della Salute di Torino
AO Cuneo
Bonifacio M; Cavo M; Vianelli N; Paglia S; Bartoletti D; Abruzzese E; Cuneo A; Lemoli RM; Semenzato G; Cilloni D; Pane F; Palandri F; Krampera M; Mazzoni C; Auteri G; Elli EM; Palumbo GA; Venturi M; Scaffidi L; Isidori A; Biondo M; Pugliese N; Bocchia M; Martino B; Miglino M; Bosi C; Crugnola M; Tieghi A; Heidel FH; et alii...
Machine learning-based prediction of in-hospital death for patients with takotsubo syndrome: The InterTAK-ML model. in European journal of heart failure
2023
AO Cuneo
AOU Città della Salute di Torino
De Filippo O; Cammann VL; Pancotti C; Di Vece D; Silverio A; Schweiger V; Niederseer D; Szawan KA; Würdinger M; Koleva I; Dusi V; Bellino M; Vecchione C; Parodi G; Bossone E; Gili S; Neuhaus M; Franke J; Meder B; Jaguszewski M; Noutsias M; Knorr M; Jansen T; Dichtl W; von Lewinski D; Burgdorf C; Kherad B; Tschöpe C; Sarcon A; et alii...
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study. in Cancers / Cancers (Basel). 2023 Jul 21;15(14):3706. doi: 10.3390/cancers15143706.
2023
AO Cuneo
AOU Città della Salute di Torino
Palandri F; Rossi E; Auteri G; Breccia M; Paglia S; Benevolo G; Elli EM; Cavazzini F; Binotto G; Tieghi A; Tiribelli M; Heidel FH; Bonifacio M; Pugliese N; Caocci G; Crugnola M; Mendicino F; D'Addio A; Tomassetti S; Martino B; Polverelli N; Ceglie S; Mazzoni C; Mullai R; Ripamonti A; Garibaldi B; Pane F; Cuneo A; Krampera M; et alii...
Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network report. in Hematological oncology / Hematol Oncol. 2023 Feb;41(1):201-204. doi: 10.1002/hon.3047. Epub 2022 Aug 19.
2023
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Novara
Reda G; Marasca R; Moia R; Cuneo A; Chiurazzi F; Orsucci L; Gottardi D; De Paoli L; Maccaferri M; Ballotta L; Foà R;
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study. in American journal of hematology / Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.
2023
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Herishanu Y; Gentile M; Cuneo A; Perry C; Gattei V; Gaidano G; Trentin L; Foà R; Olivieri J; Neri A; Rossi D; Chiarenza A; Visentin A; Pietrasanta D; Loseto G; Zucchetto A; Bomben R; Braester A; Sportoletti P; Laurenti L; Murru R; Aviv A; Varettoni M; Coscia M; Tadmor T; Shvidel L; Reda G; Ruchlemer R; Mauro FR; et alii...
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study. in Hematological oncology / Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1.
2023
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Mattiello V; Rigolin GM; Gentile M; Moia R; Scortechini I; Sportoletti P; Catania G; Loseto G; Chiurazzi F; Malerba L; De Paolis MR; Angeletti I; Ferrari A; Baratè C; Giordano A; Quaresmini G; Farina L; Leone MMA; Fresa A; Piciocchi A; Vitale C; Visentin A; Reda G; Innocenti I; Autore F; Gattei V; Coscia M; Trentin L; Foà R; et alii...
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.
2023
AO Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara
Starza ID; Cuneo A; Foà R; Vignetti M; Piciocchi A; Guarini A; Del Giudice I; Fazi P; Albano F; Neri A; De Novi LA; De Propris MS; Nanni M; Molinari MC; Visentin A; Vitale C; Mattiello V; Pietrasanta D; Liberati AM; Giordano A; Deodato M; Galieni P; Patrizi VB; Gottardi D; Tani M; Arcari A; Musuraca G; Levato L; Marchetti M; et alii...
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study. in Leukemia / Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18.
2023
AO Cuneo
Gattei V; Del Poeta G; Foà R; Di Raimondo F; Tafuri A; Zaja F; Fronza G; Morabito F; Gentile M; Cuneo A; Del Principe MI; Postorino M; Laureana R; Olivieri J; Chiarenza A; Reda G; Laurenti L; Marasca R; Bulian P; Degan M; Polesel J; Tissino E; Pozzo F; Zucchetto A; Papotti R; Vit F; Bittolo T; Rossi FM; Bomben R; et alii...
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. in American journal of hematology / Am J Hematol. 2022 May;97(5):E176-E180. doi: 10.1002/ajh.26502. Epub 2022 Feb 25.
2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Novara
Mauro FR; Trentin L; Foa' R; Tedeschi A; Gaidano G; Cuneo A; Coscia M; Guarente V; Noto A; Ielo C; Deodato M; Del Poeta G; Stelitano C; Moia R; Giordano A; Levato L; Rigolin GM; Gentile M; Murru R; De Paoli L; Laurenti L; Vitale C; Ciolli S; Chiarenza A; Sportoletti P; Frustaci AM; Visentin A; Reda G; Giannarelli D; et alii...
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. in Blood advances / Blood Adv. 2022 Mar 22;6(6):1742-1753. doi: 10.1182/bloodadvances.2021004821.
2022
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
Baccarani M; Foà R; Fazi P; Vignetti M; Cavo M; Sartor C; Paolini S; Granier M; Wang M; Zhu Z; Abbenante MC; Galieni P; Fabbiano F; Trappolini S; Tosi P; Bonifacio M; Martelli MP; D'Ardia S; Cuneo A; Tedeschi A; Frison L; Bocchia M; Vitale A; Candoni A; Selleri C; Simonetti F; Lunghi M; de Fabritiis P; Lemoli RM; et alii...
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. in American journal of hematology / Am J Hematol. 2022 Mar 1;97(3):E95-E99. doi: 10.1002/ajh.26437. Epub 2021 Dec 21.
2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Alessandria
Trentin L; Cuneo A; Foà R; Laurenti L; Molica S; Coscia M; Pietrasanta D; Marchetti M; Murru R; Gentile M; Rigolin GM; Piazza F; Scarfò L; Pravato S; Sportoletti P; Vitale C; Reda G; Fresa A; Quaglia FM; Ciolli S; Cibien F; Mauro FR; Visentin A;
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. in Haematologica / Haematologica. 2022 Jun 1;107(6):1470-1473. doi: 10.3324/haematol.2021.280325.
2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Novara
Cuneo A; Laurenti L; Ghia P; Foà R; Trentin L; Pompili M; Tedeschi A; Mauro FR; Del Poeta G; Scarfò L; Autore F; Tomasso A; Di Sevo D; Arena V; Deodato M; Ielo C; Frustaci AM; Piciocchi A; Rughini A; Cassin R; Albano F; Quaglia FM; Pennese E; Moia R; Gentile M; Murru R; Motta M; Coscia M; Visentin A; et alii...
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. in Cancer / Cancer. 2022 Jul 1;128(13):2449-2454. doi: 10.1002/cncr.34216. Epub 2022 Apr 1.
2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
Trawinska MM; Cuneo A; Bocchia M; Krampera M; Pane F; Lemoli RM; Cilloni D; Vianelli N; Cavo M; Breccia M; Palumbo GA; Micucci G; Ottaviani E; Martino B; Crugnola M; Binotto G; Bosi C; Pugliese N; Beggiato E; Fava C; Cavazzini F; Tieghi A; Benevolo G; Miglino M; Heidel FH; Polverelli N; Tiribelli M; Auteri G; Caocci G; et alii...
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study. in Cancers / Cancers (Basel). 2022 Jan 27;14(3):654. doi: 10.3390/cancers14030654.
2022
AO Cuneo
AOU Novara
Stefoni V; Tani M; Zinzani PL; Petrini M; Tisi MC; Arcari A; Kovalchuk S; Pozzi S; Musuraca G; Rosignoli C; Cantonetti M; D'Alò F; Luzi D; Pane F; Gini G; Visco C; Cuneo A; Margiotta Casaluci G; Stefani PM; Patti C; Casadei B; Argnani L; Broccoli A;
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. in Blood advances / Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.
2022
ASL Torino 5
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
Pilerci S; Pinto A; Ramadan S; Marchesi F; Cavo M; Arcaini L; Mina R; Corradini P; Tosi P; Lanza F; Della Porta M; Krampera M; Candoni A; Tisi MC; Cuneo A; Conconi A; Selleri C; Vallisa D; Venditti A; Visani G; Gambacorti-Passerini C; La Barbera EO; Rigacci L; Armiento D; Corso A; Cilloni D; Cardinali V; Bocchia M; Galimberti S; et alii...
Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. in Clinical research in cardiology : official journal of the German Cardiac Society / Clin Res Cardiol. 2022 Feb;111(2):186-196. doi: 10.1007/s00392-021-01857-4. Epub 2021 May 19.
2022
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino
ASL Torino 4
ASL Cuneo 1
Ghadri JR; Templin C; Saito S; Kobayashi Y; Lüscher TF; Ruschitzka F; Shimizu W; Rihal CS; Rickli H; Prasad A; Bax JJ; Böhm M; Winchester DE; Ukena C; Jörg L; Bianco M; Bilato C; Paolini C; Maier LS; Liu K; Di Mario C; Hauck C; Bridgman P; Galuszka J; Poglajen G; Carrilho-Ferreira P; Pinto FJ; Chan C; Meyer P; et alii...
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV. in Hematological oncology / Hematol Oncol. 2022 Dec;40(5):846-856. doi: 10.1002/hon.3048. Epub 2022 Aug 12.
2022
AO Cuneo
ASL Torino 5
AOU Città della Salute di Torino
Passamonti F; Arcaini L; Bruno R; Antonio Grossi P; Corradini P; Pagano L; Busca A; Giuliani N; Luppi M; Tosi P; Mohamed S; Corso A; Rigacci L; Giovanni Della Porta M; Lanza F; Venditti A; Massimo Lemoli R; Billio A; Gentile M; Falini B; Turrini M; Tafuri A; Morotti A; Chiara Tisi M; Galimberti S; Coviello E; Trentin L; Cuneo A; Bocchia M; et alii...
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. in Journal of hematology & oncology / J Hematol Oncol. 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0.
2022
AO Cuneo
ASL Vercelli
ASL Cuneo 1
AO Alessandria
Stamatopoulos K; Carrier M; Ghia P; Cuneo A; Segundo LYS; Yassin M; Coscia M; Rambaldi A; Montserrat E; Foà R; Wróbel T; Wasik-Szczepanek E; Visentin A; Vitale C; Vukovic V; Varettoni M; Tomic K; Tonino S; van Gelder M; Van Der Spek E; Trentin L; Te Raa D; Stanca O; Stavroyianni N; Sportoletti P; Špa?ek M; Shrestha A; Šimkovi? M; Smirnova S; et alii...
Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. in Journal of clinical medicine / J Clin Med. 2022 Apr 7;11(8):2076. doi: 10.3390/jcm11082076.
2022
AO Alessandria
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
Cuneo A; Marchetti M; Vitale C; Coscia M; Scarfò L; Visentin A; Vasile A; Rigolin GM;
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. in Haematologica / Haematologica. 2022 Apr 1;107(4):868-876. doi: 10.3324/haematol.2021.278304.
2022
AO Cuneo
Visentin A; Bonaldi L; Rigolin GM; Mauro FR; Martines A; Frezzato F; Pravato S; Gargarella LR; Bardi MA; Cavallari M; Volta E; Cavazzini F; Nanni M; Facco M; Piazza F; Guarini A; Foà R; Semenzato G; Cuneo A; Trentin L;
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study. in Frontiers in oncology / Front Oncol. 2022 Nov 21;12:1033413. doi: 10.3389/fonc.2022.1033413. eCollection 2022.
2022
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
Trentin L; Coscia M; Laurenti L; Foà R; Cuneo A; Ghia P; Reda G; Scarfò L; Cellini A; Angotzi F; Marchetti M; Pravato S; Molica S; Murru R; Gozzetti A; Gentile M; Quaglia FM; Rigolin GM; Sportoletti P; Vitale C; Sanna A; Cibien F; Mattiello V; Mauro FR; Catania G; Fresa A; Visentin A;
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AO Alessandria
AOU Novara
Foà R; Chiarenza A; Orsucci L; Penna G; Levato L; Gottardi D; Derenzini E; Gattei V; Gozzetti A; Gentile M; Sanna A; Olivieri J; Murru R; Baratè C; Leone M; Stefoni V; Malerba L; Ibatici A; Tisi MC; Marasca R; Chiurazzi F; Varettoni M; Del Poeta G; Farina L; Marchetti M; Foglietta M; Giordano A; Re F; De Paoli L; et alii...
Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors. in BMJ supportive & palliative care / BMJ Support Palliat Care. 2021 May 3:bmjspcare-2020-002312. doi: 10.1136/bmjspcare-2020-002312.
2021
AO Cuneo
Oswald LB; Venditti A; Cella D; Cottone F; Candoni A; Melillo L; Cairoli R; Storti G; Salutari P; Luppi M; Albano F; Martelli MP; Cuneo A; Tafuri A; Trisolini SM; Tieghi A; Fazi P; Vignetti M; Efficace F;
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. in American journal of hematology / Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Gentile M; Gattei V; Foà R; Ferrarini M; Polliack A; Gaidano G; Trentin L; Cuneo A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Neri A; Bomben R; Biagi A; Del Giudice I; Angeletti I; Galimberti S; Rago A; Caracciolo D; Cassin R; D'Arrigo G; Mendicino F; Botta C; Martino EA; Vigna E; Zucchetto A; Rossi FM; Scortechini I; et alii...
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. in Cancers / Cancers (Basel). 2021 Jun 29;13(13):3240. doi: 10.3390/cancers13133240.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Trentin L; Gentile G; Girmenia C; Martelli M; Gaidano G; Foà R; Cuneo A; Tedeschi A; Molica S; Coscia M; Noto A; Guarente V; Stelitano C; Del Poeta G; Giordano A; Rigolin GM; De Paoli L; Murru R; Gentile M; Levato L; Ielo C; Laurenti L; Ciolli S; Vitale C; Frustaci AM; Chiarenza A; Sportoletti P; Reda G; Visentin A; et alii...
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. in Blood / Blood. 2021 Jun 24;137(25):3507-3517. doi: 10.1182/blood.2020008201.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Boccadoro M; Mauro FR; Foà R; Tedeschi A; Scarfò L; Gaidano G; Trentin L; Cuneo A; Orsucci L; Reda G; Perutelli F; De Paoli L; Montalbano MC; Boccellato E; Gentile M; Rivela P; Marchetti M; Pennese E; Rigolin GM; Murru R; Laurenti L; Cassin R; Vassallo F; Visentin A; Zamprogna G; Schiattone L; Griggio V; Porrazzo M; Vitale C; et alii...
Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. in ESC heart failure / ESC Heart Fail. 2021 Jun;8(3):1924-1932. doi: 10.1002/ehf2.13165. Epub 2021 Mar 13.
2021
AO Cuneo
AOU Città della Salute di Torino
Templin C; Ghadri JR; Lüscher TF; Ruschitzka F; Bax JJ; Crea F; Münzel T; Di Mario C; Katus HA; Horowitz JD; Bauersachs J; Thiele H; Borggrefe M; Schunkert H; Hasenfuß G; Pieske BM; Opolski G; Braun-Dullaeus RC; Rottbauer W; Felix SB; Pinto FJ; Widimský P; Böhm M; Maier LS; Nguyen TH; Rickli H; Pestana G; Schulze PC; Bianco M; et alii...
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. in Blood cancer journal / Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1.
2021
AO Cuneo
AOU Città della Salute di Torino
Breccia M; Bonifacio M; Vianelli N; Cavo M; Iurlo A; Krampera M; Lemoli RM; Semenzato G; Cuneo A; Pane F; Stella R; Ciantia F; Trawinska MM; Cattaneo D; Scaffidi L; Bartoletti D; Auteri G; Heidel F; Pugliese N; Bosi C; Caocci G; Isidori A; Crugnola M; Bergamaschi M; Binotto G; Cavazzini F; Latagliata R; Tiribelli M; Tieghi A; et alii...
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. in Leukemia / Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Sportoletti P; Laurenti L; Gattei V; Gaidano G; Polliack A; Foà R; Rossi D; Cuneo A; Di Raimondo F; Rigolin GM; Bomben R; Biagi A; Del Giudice I; Angeletti I; Rago A; Arrigo G; Vigna E; Botta C; Tripepi G; Fraticelli V; Zucchetto A; Scortechini I; Loseto G; Consoli U; Rossi FM; Pietrasanta D; Murru R; Chiarenza A; Condoluci A; et alii...
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.
2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AO Alessandria
AOU Novara
Cuneo A; Foà R; Rigolin GM; Piciocchi A; Fazi P; Neri A; Guarini A; Nanni M; Raponi S; Della Starza I; Murru R; Ruocco V; Del Giudice I; De Propris MS; Varettoni M; Ibatici A; Chiarenza A; Laurenti L; Gentile M; Molinari A; Tani M; Musuraca G; Gottardi D; Zinzani PL; Gozzetti A; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. in Blood / Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883.
2021
AO Cuneo
AO Alessandria
Mariglia P; Vignetti M; Peragine N; Nanni M; Marchetti M; Trentin L; Sportoletti P; Molica S; Albano F; Reda G; Arena V; Piciocchi A; Cafforio L; Ilari C; Raponi S; Cura F; García-Jacobo RE; Melandri A; Bardi A; Del Giudice I; Rigolin GM; Guarini A; Mauro FR; Foà R; Cuneo A;
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. in Leukemia / Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Ghia P; Stamatopoulos K; Cuneo A; Montserrat E; Foà R; Yassin M; Coscia M; Rambaldi A; San Segundo LY; Visentin A; Vitale C; Wasik-Szczepanek E; Wróbel T; van Kampen R; Varettoni M; Tadmor T; Te Raa D; Tonino SH; van Gelder M; Van Der Spek E; Trentin L; Sportoletti P; Stanca O; Stavroyianni N; Špa?ek M; Šimkovi? M; Shrestha A; Saghumyan G; Ruchlemer R; et alii...
Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry. in Journal of the American Heart Association / J Am Heart Assoc. 2021 Aug 3;10(15):e014059. doi: 10.1161/JAHA.119.014059. Epub 2021 Jul 28.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU San Luigi di Orbassano
Akin I; Borggrefe M; Duru F; Ruschitzka F; Bax JJ; Lüscher TF; Crea F; Münzel T; Di Mario C; Katus HA; Horowitz JD; Bauersachs J; Thiele H; Pieske BM; Schunkert H; Hasenfuß G; Rottbauer W; Braun-Dullaeus RC; Felix SB; Opolski G; Pinto FJ; Widimský P; Maier LS; Nguyen TH; Böhm M; Pestana G; Jörg L; Rickli H; Bianco M; et alii...
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. in Cancer / Cancer. 2021 Aug 1;127(15):2657-2665. doi: 10.1002/cncr.33541. Epub 2021 Apr 1.
2021
AO Cuneo
AOU Città della Salute di Torino
Bonifacio M; Palumbo GA; Vianelli N; Cavo M; Lemoli RM; Cuneo A; Krampera M; Semenzato G; Pane F; Latagliata R; Heidel FH; Bosi C; Crugnola M; Micucci G; Masselli E; Polverelli N; Scaffidi L; Stella R; Trawinska MM; Cattaneo D; Auteri G; Caocci G; Pugliese N; Binotto G; Abruzzese E; Tieghi A; Iurlo A; Martino B; Cavazzini F; et alii...
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Gentile M; Gattei V; Ferrarini M; Foà R; Polliack A; Trentin L; Cuneo A; Gaidano G; Di Raimondo F; Rossi D; Olivieri J; Jaksic O; Bomben R; Neri A; Fronza G; Rago A; Angeletti I; Cutrona G; Del Giudice I; Biagi A; Galimberti S; D'Arrigo G; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; Zucchetto A; Rossi FM; Recchia AG; et alii...
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
D Arrigo G; Murru R; Gentile M; Gattei V; Polliack A; Trentin L; Gaidano G; Di Raimondo F; Cuneo A; Cutrona G; Rossi D; Menichini P; Olivieri J; Fronza G; Monti P; Del Giudice I; Bomben R; Neri A; Angeletti I; Biagi A; Rago A; Martino EA; Cassin R; Galimberti S; Foà R; Ferrarini M; Scortechini I; Rossi FM; Zucchetto A; et alii...
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. in Hematological oncology / Hematol Oncol. 2021 Aug;39(3):326-335. doi: 10.1002/hon.2861. Epub 2021 Mar 26.
2021
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Montillo M; Foà R; Cuneo A; Gentile M; Crea E; Marasca R; Marchetti M; Vignetti M; Mauro FR; Laurenti L; Quaglia FM; Pietrasanta D; Molinari AL; Sportoletti P; Paolini R; Varettoni M; Gaidano G; Murru R; Vitagliano O; Coscia M; Farina L; Cibien F; Zamprogna G; Reda G; Arena V; Visentin A; Piciocchi A; Cavazzini F; Rigolin GM; et alii...
Second primary malignancy in myelofibrosis patients treated with ruxolitinib. in British journal of haematology / Br J Haematol. 2021 Apr;193(2):356-368. doi: 10.1111/bjh.17192. Epub 2020 Nov 21.
2021
AO Cuneo
AOU Città della Salute di Torino
Iurlo A; Cavo M; Russo D; Breccia M; Vianelli N; Lemoli RM; Semenzato G; Krampera M; Cuneo A; Catani L; Pane F; Markovic U; Stella R; Trawinska MM; Cattaneo D; D'Amore F; Scaffidi L; Martino B; Latagliata R; Gandolfi L; Auteri G; Bartoletti D; Bosi C; Isidori A; Pugliese N; Crugnola M; Heidel FH; Cavazzini F; Binotto G; et alii...
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. in European journal of haematology / Eur J Haematol. 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573. Epub 2021 Jan 28.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Gentile M; Gattei V; Ferrarini M; Foà R; Trentin L; Polliack A; Gaidano G; Cuneo A; Di Raimondo F; Rossi D; Jaksic O; Monti P; Cutrona G; Bomben R; Neri A; Fronza G; Menichini P; Biagi A; Del Giudice I; Angeletti I; Rago A; Galimberti S; Cassin R; D'Arrigo G; Mendicino F; Martino EA; Vigna E; Al-Janazreh H; Zucchetto A; et alii...
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. in Frontiers in oncology / Front Oncol. 2021 Apr 15;11:637186. doi: 10.3389/fonc.2021.637186. eCollection 2021.
2021
AO Cuneo
Puzzolo MC; Del Giudice I; Peragine N; Mariglia P; De Propris MS; Cappelli LV; Trentin L; Reda G; Cuneo A; Molica S; Piciocchi A; Arena V; Mauro FR; Guarini A; Foà R;
Coexistence and outcome of coronary artery disease in Takotsubo syndrome. in European heart journal / Eur Heart J. 2020 Sep 7;41(34):3255-3268. doi: 10.1093/eurheartj/ehaa210.
2020
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AO Cuneo
Katus HA; Rottbauer W; Braun-Dullaeus RC; Pinto FJ; Maier LS; Borggrefe M; Crea F; Bianco M; Schulze PC; Rihal CS; Prasad A; Di Mario C; Carrilho-Ferreira P; Poglajen G; Ukena C; Galuszka J; Widimský P; Winchester DE; Tousek P; Polednikova K; Horowitz JD; Gilyarov M; Shilova A; Gilyarova E; Akin I; El-Battrawy I; Lairez O; Delmas C; Beug D; et alii...
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. in Blood cancer journal / Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3.
2020
AOU Città della Salute di Torino
AO Cuneo
AO Alessandria
AOU Novara
Gattei V; Morabito F; Ferrarini M; Gaidano G; Cuneo A; Foà R; Trentin L; Fronza G; Cutrona G; Di Raimondo F; Angeletti I; Bomben R; Neri A; D'Arrigo G; Tripepi G; Vitale C; Al-Janazreh H; Rossi FM; Zucchetto A; Scortechini I; Consoli U; Loseto G; Pietrasanta D; Bossio S; Moia R; Recchia AG; Lucia E; Mendicino F; Vigna E; et alii...
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. in Leukemia / Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.
2020
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Foà R; Rambaldi A; Montserrat E; Rossi G; Stamatopoulos K; Coscia M; Stavroyianni N; Strugov V; Tam C; Zdrenghea M; Shah N; Shrestha A; Stanca O; Ortiz Pareja M; Papaioannou M; Rossi D; Kalashnikova O; Hakobyan Y; Doubek M; Enrico A; Dimou M; Andres M; Chiarenza A; Nikitin E; Dos Santos G; Barna G; Yassin M; Pocali B; Sportoletti P; et alii...
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). in Haematologica / Haematologica. 2020 Nov 1;105(11):2671-2674. doi: 10.3324/haematol.2019.235705.
2020
AOU Città della Salute di Torino
AO Cuneo
AO Alessandria
Foà R; Guarini AR; Raponi S; De Propris MS; Della Starza I; Del Giudice I; Albano F; Cuneo A; Neri A; Piciocchi A; Vignetti M; Nanni M; Musolino C; Battistini R; Del Poeta G; Pietrasanta D; Gozzetti A; Liberati AM; Reda G; Tedeschi A; Re F; Soddu S; Mauro FR; Angelucci E; Zaja F; Coscia M; Ilariucci F; Molica S;
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. in Cancer medicine / Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.
2020
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Novara
Cucci R; Vignetti M; Foà R; Ghia P; Ferrarini I; Cimino G; Cavallari M; Medina Perez A; Mauro FR; de la Serna J; Coscia M; Di Raimondo F; Molica S; Farina L; Gaidano G; Doubek M; Ilariucci F; Tedeschi A; Marchetti M; Spacek M; Trentin L; Billio A; Ujjani CS; Roeker L; Orlandi EM; Shah NN; Schuster SJ; Pu JJ; Sehgal AR; et alii...
Age-Related Variations in Takotsubo Syndrome. in Journal of the American College of Cardiology / J Am Coll Cardiol. 2020 Apr 28;75(16):1869-1877. doi: 10.1016/j.jacc.2020.02.057.
2020
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AO Cuneo
Pieske BM; Hasenfuß G; Rottbauer W; Braun-Dullaeus RC; Felix SB; Widimský P; Pinto FJ; Maier LS; Böhm M; Nguyen TH; Pestana G; Rickli H; Jörg L; Bianco M; Schulze PC; Liu K; Rihal CS; Prasad A; Al-Shammari A; Din J; Himi T; Ishibashi I; Takahara M; Shoji T; Kobayashi Y; Bilato C; Paolini C; Hauck C; Carrilho-Ferreira P; et alii...
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. in Blood / Blood. 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8.
2019
AO Cuneo
Amadori S; Arcese W; Lo-Coco F; Voso MT; Lavorgna S; Ottone T; Irno-Consalvo M; Del Principe MI; Buccisano F; Vignetti M; Maurillo L; Fazi P; La Sala E; Alati C; Fracchiolla NS; Capelli D; Foà R; Tieghi A; Chierichini A; Fabbiano F; Tafuri A; Cuneo A; Albano F; Mazza P; Martelli MP; Luppi M; Martinelli G; Lanza F; Storti G; et alii...
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. in Hematological oncology / Hematol Oncol. 2019 Oct;37(4):508-512. doi: 10.1002/hon.2655. Epub 2019 Aug 5.
2019
AOU Città della Salute di Torino
AO Cuneo
Semenzato G; Trentin L; Foà R; Cuneo A; Coscia M; Cassin R; Laurenti L; Tedeschi A; Cesini L; Piazza F; Rigolin GM; Molica S; Vitale C; Reda G; Autore F; Mauro FR; Deodato M; Visentin A;
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. in British journal of haematology / Br J Haematol. 2019 Oct;187(1):e8-e11. doi: 10.1111/bjh.16123. Epub 2019 Jul 31.
2019
AOU Città della Salute di Torino
AO Cuneo
Laurenti L; Foà R; Cuneo A; Scarfò L; Tedeschi A; Efremov DG; D'Arena G; Gentile M; Levato L; Murru R; Sportoletti P; Coscia M; Ciolli S; Ibatici A; Reda G; Rigolin GM; Del Poeta G; Trentin L; Schiattone L; Mauro FR; Frustaci A; Piciocchi A; Autore F; Morelli F; Innocenti I;
Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. in European journal of heart failure / Eur J Heart Fail. 2019 Nov;21(11):1469-1472. doi: 10.1002/ejhf.1561. Epub 2019 Aug 27.
2019
AOU Città della Salute di Torino
AO Cuneo
Templin C; Ghadri JR; Ruschitzka F; Lüscher TF; Bax JJ; Crea F; Münzel T; Di Mario C; Horowitz J; Katus HA; Bauersachs J; Thiele H; Schunkert H; Pieske BM; Hasenfuß G; Rottbauer W; Braun-Dullaeus RC; Opolski G; Felix SB; Borggrefe M; Widimský P; Pinto FJ; Maier LS; Böhm M; Kobayashi Y; Nguyen TH; Rickli H; Jörg L; Bianco M; et alii...
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. in Cancers / Cancers (Basel). 2019 Jun 26;11(7):896. doi: 10.3390/cancers11070896.
2019
AOU Città della Salute di Torino
AO Cuneo
Laurenti L; Ferrajoli A; Foà R; Sica S; Visentin A; Reda G; Tisi MC; Vitale C; Rigolin GM; Ferretti A; Efremov DG; Vincelli D; Murru R; D'Arena G; Falcucci P; Molica S; Morabito F; Gentile M; Frustaci AM; Mauro FR; Gozzetti A; Cuneo A; Visco C; Coscia M; Cortelezzi A; Trentin L; Corrente F; Innocenti I; Strati P; et alii...
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. in Hematological oncology / Hematol Oncol. 2018 Feb;36(1):285-290. doi: 10.1002/hon.2429. Epub 2017 May 17.
2018
AOU Città della Salute di Torino
AO Cuneo
Bonifacio M; Vianelli N; Cavo M; Scaffidi L; Cuneo A; Abruzzese E; Palumbo GA; Kallenberg L; Spinsanti M; Latagliata R; Martino B; Buccisano F; Heidel FH; Binotto G; Isidori A; Crugnola M; Polverelli N; Sgherza N; Bergamaschi M; Breccia M; Cavazzini F; Tieghi A; Benevolo G; Tiribelli M; Palandri F;
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. in Haematologica / Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8.
2017
AO Ordine Mauriziano
AOU Città della Salute di Torino
AO Cuneo
Piciocchi A; Boncompagni R; Orlando S; Cuneo A; Galieni P; Marasca R; Vannata B; Pozzato G; Efremov DG; Molica S; Coscia M; Massaia M; D'Arena G; Del Poeta G; Mannina D; Mauro FR; Ciolli S; Autore F; Innocenti I; Laurenti L; Vincelli D; Liberati AM; Russo F; Foá R;
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. in Oncotarget / Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.
2017
AOU Città della Salute di Torino
AO Cuneo
Cuneo A; Cavo M; Vianelli N; Breccia M; Bacchi Reggiani ML; Merli F; Fanin R; Lemoli RM; Vitolo U; Di Raimondo F; Aversa F; Catani L; Sabattini E; Spinsanti M; De Matteis G; Anaclerico B; Cerqui E; de Marchi F; Scaffidi L; Di Veroli A; Latagliata R; Bosi C; Crugnola M; Ibatici A; Cavazzini F; Tieghi A; Bergamaschi M; Polverelli N; D'Adda M; et alii...